May 17, 2021

University of Tsukuba and TNAX Biopharma Corporation identified an antibody which ameliorates complications associated with GVHD, and findings were published in Proc Natl Acad Sci USA(Press Release).

November 29, 2019

Series A2 funding closed.(jafcomucapnissay-cap)  

February 25, 2019

Our article was on the on line magazine “Nikkei Bitotech”.(press release)  

November 30, 2018

Series A funding closed.(jafcomucapnissay-cap)  

November 30, 2018

TNAX Biopharma was authorized as a startup originated from University of Tsukuba.(press release, university of Tsukuba)